4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-033973
Chief Executive Officer sold 32,410 shares at $185.60 ($6,015,296)
- Chief Executive Officer acquired 32,410 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT Chief Executive Officer | 2026-02-02 | Option exercise 10b5-1 | +32,410 | $8.02 | $259,928 | 39,639 | D: show line 1 in the form |
| TABUTEAU HERRIOT Chief Executive Officer | 2026-02-02 | Sale 10b5-1 | −32,410 | $185.60 | $6,015,296 | 7,229 | D: show line 2 in the form |
| Open-market sales · 32,410 sh · avg $185.60 · $6,015,296 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT Chief Executive Officer | 2026-02-02 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −32,410 | 0 | D: show line 3 in the form |
Loading xslF345X05/ownership.xml…